Marco L Leung

Dr. Marco L Leung

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2024 in The Journal of Molecular Diagnostics
Verified
Journal Article
Open access
MLMarco L Leung
Marco L Leung
ZAZied Abdullaev
Zied Abdullaev
Lucas Santana dos SantosLucas Santana dos Santos
Lucas Santana dos Santos
JSJohn M. Skaugen
John M. Skaugen
SMStephen Moore
Stephen Moore
JJJianling Ji
Jianling Ji
Microarray-based methylation profiling has emerged as a valuable tool for refining diagnoses and revealing novel tumor subtypes, particularly in central nervous system tumors. Despite the increasing adoption of this technique in clinical genomic laboratories, no technical standards have been published in establishing minimum criteria for test validation. A working group with experience and expertise in DNA-based methylation profiling tests on central nervous system tumors collaborated to develop practical discussion points and focus on important considerations for validating this test in clinical laboratory settings. The experience in validating this methodology in a clinical setting is summarized. Specifically, the advantages and challenges associated with utilizing an in-house classifier compared with a third-party classifier are highlighted. Additionally, experiences in demonstrating the assay's sensitivity and specificity, establishing minimum sample criteria, and implementing quality control metrics are described. As methylation profiling for tumor classification expands to other tumor types and continues to evolve for various other applications, the critical considerations described here are expected to serve as a guidance for future efforts in establishing professional guidelines for this assay.

27 March 2023 in Genetics in Medicine Open
Verified
Journal Article
Open access
YAYassmine Akkari
Yassmine Akkari
SDSheila Dobin
Sheila Dobin
RBRobert G. Best
Robert G. Best
MLMarco L Leung
Marco L Leung
Workforce shortages are observed in many sectors of the economy, including clinical genomics laboratories. Although medical technologists are essential for the primary functions of laboratory operations and many institutions in the United States have reported acute staff shortages, we are unaware of any recent studies that provide concrete data detailing workforce needs. In this report, we summarize the results of a technologist-based survey sent to clinical laboratory directors across the United States. The survey was designed to provide detailed and objective evidence on the current landscape of the technologist workforce in clinical cytogenetics, molecular genetics, and laboratories that have combined both disciplines. Survey questions included demographics, salaries across career stages, retention trends, and hiring requirements and challenges. Analysis of the survey data from 70 US-based submissions showed that cytogenetics laboratories had higher proportion of unfilled technologist positions, whereas molecular laboratories had more applications for each open positions. The technologist retention rate in molecular laboratories was higher than that in cytogenetics. The lack of adequately trained applicants and competitive salary offers by other laboratories were cited as top barriers for filling technologist positions. The results from this survey will serve as normative data in generating solutions to address acute workforce needs in the United States.

3 October 2023 in Muscle & Nerve
Verified
Journal Article
Closed access
AMAlayne P. Meyer
Alayne P. Meyer
JMJianing Ma
Jianing Ma
GBGuy Brock
Guy Brock
SHSayaka Hashimoto
Sayaka Hashimoto
CCCatherine E. Cottrell
Catherine E. Cottrell
KFKevin M. Flanigan
Kevin M. Flanigan

21 January 2022 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
MLMarco L Leung
Marco L Leung
JJJianling Ji
Jianling Ji
SBSamuel Baker
Samuel Baker
JBJillian G. Buchan
Jillian G. Buchan
TSTheru A. Sivakumaran
Theru A. Sivakumaran
ASAvni B. Santani
Avni B. Santani

16 June 2022 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
MMMariam T. Mathew
Mariam T. Mathew
AAAustin Antoniou
Austin Antoniou
NRNaveen Ramesh
Naveen Ramesh
MHMin Hu
Min Hu
JGJeffrey Gaither
Jeffrey Gaither
MLMarco L Leung
Marco L Leung

23 January 2024 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
JOJoie O. Olayiwola
Joie O. Olayiwola
MMMohammad Marhabaie
Mohammad Marhabaie
DKDaniel Koboldt
Daniel Koboldt
TMTheodora Matthews
Theodora Matthews
ASAmy Siemon
Amy Siemon
MLMarco L Leung
Marco L Leung
Background: Chromosomal microarray (CMA) is commonly utilized in the obstetrics setting. CMA is recommended when one or more fetal structural abnormalities is identified. CMA is also commonly used to determine genetic etiologies for miscarriages, fetal demise, and confirming positive prenatal cell‐free DNA screening results.Methods: In this study, we retrospectively examined 523 prenatal and 319 products‐of‐conception (POC) CMA cases tested at Nationwide Children's Hospital from 2011 to 2020. We reviewed the referral indications, the diagnostic yield, and the reported copy number variants (CNV) findings. Results.In our cohort, the diagnostic yield of clinically significant CNV findings for prenatal testing was 7.8% (n = 41/523) compared to POC testing (16.3%, n = 52/319). Abnormal ultrasound findings were the most common indication present in 81% of prenatal samples. Intrauterine fetal demise was the common indication identified in POC samples. The most common pathogenic finding observed in all samples was isolated trisomy 21, detected in seven samples.Conclusion: Our CMA study supports the clinical utility of prenatal CMA for clinical management and identifying genetic etiology in POC arrays. In addition, it provides insight to the spectrum of prenatal and POC CMA results as detected in an academic hospital clinical laboratory setting that serves as a reference laboratory.